+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibody-oligonucleotide Conjugates Market by Oligonucleotide Type, Conjugation Methodology, Targeting Strategy, Application, End-User - Global Forecast to 2030- Product Image
Antibody-oligonucleotide Conjugates Market by Oligonucleotide Type, Conjugation Methodology, Targeting Strategy, Application, End-User - Global Forecast to 2030- Product Image
Sale

Antibody-oligonucleotide Conjugates Market by Oligonucleotide Type, Conjugation Methodology, Targeting Strategy, Application, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6055232
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antibody-oligonucleotide conjugates market is accelerating as organizations increasingly seek advanced tools for precise gene modulation, targeted therapeutics, and high-specificity diagnostics. As innovation intensifies and adoption broadens across sectors, industry leaders are capitalizing on new opportunities in both developed and emerging markets.

Market Snapshot: Antibody-Oligonucleotide Conjugates Market Outlook

The Antibody-oligonucleotide Conjugates Market grew from USD 3.82 billion in 2024 to USD 4.15 billion in 2025. It is expected to continue growing at a CAGR of 8.85%, reaching USD 6.36 billion by 2030.

Scope & Segmentation

This report examines the antibody-oligonucleotide conjugates market across a comprehensive set of endpoints, ensuring senior decision-makers receive complete insight into evolving trends and opportunities. The research covers technological advances, regional performance, and core application areas.

  • Oligonucleotide Type: DNA, morpholinos, peptide nucleic acids, RNA
  • Conjugation Methodology: Covalent binding-based, electrostatic interaction-based, avidin-biotin affinity-based
  • Targeting Strategy: Cell surface receptors, intracellular targets, pathogen-associated targets
  • Application: Diagnostics, research, therapeutics (autoimmune disorders, cardiovascular diseases, infectious diseases, oncology, rare diseases)
  • End-User: Academic and research institutions, contract research organizations, pharmaceutical and biotechnology companies
  • Geography: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (major markets such as United Kingdom, Germany, France, Saudi Arabia, South Africa, and others), Asia-Pacific (including China, India, Japan, Australia, and more)
  • Company Coverage: Market developments from key players such as AbbVie Inc., AstraZeneca PLC, Agilent Technologies, Eli Lilly Company, WuXi AppTec, Thermo Fisher Scientific, and others

Key Takeaways for Senior Decision-Makers

  • Conjugation technologies are rapidly evolving, enabling higher stability and targeted delivery for therapeutic and diagnostic platforms.
  • Regulatory agencies are increasingly clarifying standards for conjugate modalities, which supports streamlined market entry and encourages investment.
  • Commercial alliances between biopharma leaders and specialized service providers are facilitating end-to-end workflows, accelerating project timelines from discovery through clinical manufacturing.
  • Regional initiatives, particularly in Asia-Pacific, are fostering rapid adoption and innovation through government-backed biotechnology programs and growing manufacturing infrastructures.
  • Intellectual property strategies, including patented linker and backbone chemistries, are critical in differentiating offerings amid increasing competition.

Impact of 2025 US Tariffs

Recent US tariff adjustments have prompted raw material suppliers and manufacturers to re-evaluate sourcing strategies, strengthen local production capacities, and form new alliances to mitigate cost pressures. These shifts are reflected downstream, as contract organizations and pharmaceutical procurement teams implement revised pricing models and renegotiate supply agreements for greater budget predictability. Additionally, process improvements in manufacturing have helped counteract rising costs and enhanced production efficiency, equipping market participants to remain competitive during policy changes.

Primary and Secondary Methodologies Applied

Market insights derive from in-depth interviews with industry, scientific, and regulatory stakeholders, combined with analysis of corporate reports, patent filings, and government sources. Peer-reviewed literature, white papers, and proprietary databases have further validated trends and trajectories, ensuring a rigorous, accurate outlook.

Why This Report Matters

  • Enables evidence-based investment and partnership decisions by providing deep segmentation and actionable intelligence.
  • Equips strategy and procurement teams with clarity on technology adoption, regional market movements, and regulatory pathways.

Conclusion

The antibody-oligonucleotide conjugates market is shaped by ongoing technological innovation, shifting economic environments, and strategic collaboration. Organizations that align their capabilities to these evolving dynamics are positioned to drive growth and deliver differentiated solutions.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antibody-oligonucleotide Conjugates Market, by Oligonucleotide Type
8.1. Introduction
8.2. DNA
8.3. Morpholinos
8.4. Peptide Nucleic Acids
8.5. RNA
9. Antibody-oligonucleotide Conjugates Market, by Conjugation Methodology
9.1. Introduction
9.2. Covalent Binding-based
9.3. Electrostatic Interaction-based
9.4. Evidin-biotin Affinity-based
10. Antibody-oligonucleotide Conjugates Market, by Targeting Strategy
10.1. Introduction
10.2. Cell Surface Receptors
10.3. Intracellular Targets
10.4. Pathogen-Associated Targets
11. Antibody-oligonucleotide Conjugates Market, by Application
11.1. Introduction
11.2. Diagnostics
11.3. Research
11.4. Therapeutics
11.4.1. Autoimmune Disorders
11.4.2. Cardiovascular Diseases
11.4.3. Infectious Diseases
11.4.4. Oncology
11.4.5. Rare Diseases
12. Antibody-oligonucleotide Conjugates Market, by End-User
12.1. Introduction
12.2. Academic & Research Institutions
12.3. Contract Research Organizations
12.4. Pharmaceutical & Biotechnology Companies
13. Americas Antibody-oligonucleotide Conjugates Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Antibody-oligonucleotide Conjugates Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Antibody-oligonucleotide Conjugates Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Abcam plc
16.3.3. Abzena Holdings Ltd
16.3.4. Agilent Technologies, Inc.
16.3.5. AlphaThera
16.3.6. AstraZeneca PLC
16.3.7. Avidity Biosciences, Inc.
16.3.8. Bristol-Myers Squibb Company
16.3.9. Codexis, Inc.
16.3.10. Columbia Biosciences
16.3.11. Daiichi Sankyo Company, Limited
16.3.12. Eli Lilly Company
16.3.13. Exactmer Ltd
16.3.14. GenScript Biotech Corporation
16.3.15. Goodwin Biotechnology Inc.
16.3.16. Ionis Pharmaceuticals, Inc.
16.3.17. iQ Biosciences
16.3.18. Merck KGaA
16.3.19. miRecule, Inc.
16.3.20. Perseus Proteomics Inc.
16.3.21. Rockland Immunochemicals, Inc
16.3.22. Sarepta Therapeutics, Inc.
16.3.23. Tallac Therapeutics, Inc.
16.3.24. Thermo Fisher Scientific Inc.
16.3.25. UBE Corporation
16.3.26. WuXi AppTec (Shanghai) Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET MULTI-CURRENCY
FIGURE 2. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET MULTI-LANGUAGE
FIGURE 3. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY MORPHOLINOS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PEPTIDE NUCLEIC ACIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COVALENT BINDING-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ELECTROSTATIC INTERACTION-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY EVIDIN-BIOTIN AFFINITY-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CELL SURFACE RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRACELLULAR TARGETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PATHOGEN-ASSOCIATED TARGETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 47. CANADA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 50. CANADA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. CANADA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 52. CANADA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. MEXICO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 56. MEXICO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. MEXICO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 58. MEXICO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. UNITED KINGDOM ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 79. UNITED KINGDOM ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 80. UNITED KINGDOM ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. UNITED KINGDOM ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. GERMANY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 85. GERMANY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 86. GERMANY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 87. GERMANY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. GERMANY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 89. GERMANY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. FRANCE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 91. FRANCE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 92. FRANCE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 93. FRANCE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. FRANCE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 95. FRANCE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. RUSSIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 97. RUSSIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 98. RUSSIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 99. RUSSIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. RUSSIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 101. RUSSIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. ITALY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 103. ITALY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 104. ITALY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 105. ITALY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. ITALY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 107. ITALY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. SPAIN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 109. SPAIN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 110. SPAIN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 111. SPAIN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. SPAIN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 113. SPAIN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. UNITED ARAB EMIRATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 115. UNITED ARAB EMIRATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 116. UNITED ARAB EMIRATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 117. UNITED ARAB EMIRATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. UNITED ARAB EMIRATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 119. UNITED ARAB EMIRATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. SOUTH AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. DENMARK ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 133. DENMARK ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 134. DENMARK ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 135. DENMARK ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. DENMARK ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 137. DENMARK ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 143. NETHERLANDS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. QATAR ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 145. QATAR ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 146. QATAR ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 147. QATAR ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. QATAR ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 149. QATAR ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. FINLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 151. FINLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 152. FINLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 153. FINLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. FINLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 155. FINLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. SWEDEN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 157. SWEDEN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 158. SWEDEN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 159. SWEDEN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. SWEDEN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 161. SWEDEN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 162. NIGERIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 163. NIGERIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 164. NIGERIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 165. NIGERIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. NIGERIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. EGYPT ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 169. EGYPT ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 170. EGYPT ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 171. EGYPT ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. EGYPT ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 173. EGYPT ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. TURKEY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 175. TURKEY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 176. TURKEY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 177. TURKEY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. TURKEY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 179. TURKEY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. ISRAEL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. NORWAY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 187. NORWAY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 188. NORWAY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 189. NORWAY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. NORWAY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 191. NORWAY ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 192. POLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 193. POLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 194. POLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 195. POLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. POLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 197. POLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. SWITZERLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 199. SWITZERLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 200. SWITZERLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 201. SWITZERLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. SWITZERLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 203. SWITZERLAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 211. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 212. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 213. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 214. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 216. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 217. INDIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 218. INDIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 219. INDIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 220. INDIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. INDIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 222. INDIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. JAPAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 224. JAPAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 225. JAPAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 226. JAPAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. JAPAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 228. JAPAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 247. THAILAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 248. THAILAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 249. THAILAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 250. THAILAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. THAILAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 252. THAILAND ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 258. PHILIPPINES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 266. SINGAPORE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 268. SINGAPORE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 269. SINGAPORE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 270. SINGAPORE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. VIETNAM ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 272. VIETNAM ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 273. VIETNAM ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. TAIWAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 278. TAIWAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
TABLE 279. TAIWAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
TABLE 280. TAIWAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. TAIWAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 282. TAIWAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 283. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SHARE, BY KEY PLAYER, 2024
TABLE 284. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Antibody-oligonucleotide Conjugates market report include:
  • AbbVie Inc.
  • Abcam plc
  • Abzena Holdings Ltd
  • Agilent Technologies, Inc.
  • AlphaThera
  • AstraZeneca PLC
  • Avidity Biosciences, Inc.
  • Bristol-Myers Squibb Company
  • Codexis, Inc.
  • Columbia Biosciences
  • Daiichi Sankyo Company, Limited
  • Eli Lilly Company
  • Exactmer Ltd
  • GenScript Biotech Corporation
  • Goodwin Biotechnology Inc.
  • Ionis Pharmaceuticals, Inc.
  • iQ Biosciences
  • Merck KGaA
  • miRecule, Inc.
  • Perseus Proteomics Inc.
  • Rockland Immunochemicals, Inc
  • Sarepta Therapeutics, Inc.
  • Tallac Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • UBE Corporation
  • WuXi AppTec (Shanghai) Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.15 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.36 Billion
Compound Annual Growth Rate8.8%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2025 - Product Image

Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2025

  • Drug Pipelines
  • 50 Pages
  • Global
From
Large Molecule Bioanalytical Technologies Market Size, Share & Trends Analysis Report by Products & Services, Application (Biologics, Oligonucleotide Derived Drugs & Molecules), Region, with Growth Forecasts, 2025-2030 - Product Image

Large Molecule Bioanalytical Technologies Market Size, Share & Trends Analysis Report by Products & Services, Application (Biologics, Oligonucleotide Derived Drugs & Molecules), Region, with Growth Forecasts, 2025-2030

  • Report
  • 258 Pages
  • Global
From
DNA Microarray Market Size, Share & Trends Analysis Report By Type (Complementary DNA Microarrays, Oligonucleotide DNA Microarrays), By Application (Gene Expression Analysis, Genotyping), By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

DNA Microarray Market Size, Share & Trends Analysis Report By Type (Complementary DNA Microarrays, Oligonucleotide DNA Microarrays), By Application (Gene Expression Analysis, Genotyping), By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Innovation Insights: Anti-sense Oligonucleotides - Product Image

Innovation Insights: Anti-sense Oligonucleotides

  • Report
  • 51 Pages
  • Global
From
Synthetic Biology Market by Tools (Oligonucleotides, Enzymes, Synthetic Cells), Technology (Sequencing, Bioinformatics), Applications (Drug Discovery, Tissue Regeneration, Biofuel, Food, Agriculture, Consumer Care, Environmental) - Global Forecast to 2029 - Product Image

Synthetic Biology Market by Tools (Oligonucleotides, Enzymes, Synthetic Cells), Technology (Sequencing, Bioinformatics), Applications (Drug Discovery, Tissue Regeneration, Biofuel, Food, Agriculture, Consumer Care, Environmental) - Global Forecast to 2029

  • Report
  • 537 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.